Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.3% – Should You Sell?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) fell 0.3% during trading on Monday . The company traded as low as $2.98 and last traded at $3.01. 27,172 shares were traded during trading, a decline of 80% from the average session volume of 133,793 shares. The stock had previously closed at $3.02.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Kiora Pharmaceuticals in a report on Friday, March 28th.

Kiora Pharmaceuticals Stock Performance

The firm’s fifty day simple moving average is $3.08 and its 200 day simple moving average is $3.29. The stock has a market capitalization of $9.16 million, a price-to-earnings ratio of -1.04 and a beta of -0.68.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.25. Analysts forecast that Kiora Pharmaceuticals, Inc. will post 1.28 earnings per share for the current year.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC lifted its position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 200,221 shares of the company’s stock after buying an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned about 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent quarter. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.